Quantcast

Examine the Markets & Opportunities for Inhaled CNS Therapeutics With This Essential and Comprehensive Report

October 1, 2008

Research and Markets (http://www.researchandmarkets.com/research/370328/inhaled_cns_therap) has announced the addition of the “Inhaled CNS Therapeutics – Markets & Opportunities” report to their offering.

Delivering drugs to the central nervous system presents unique challenges. But, drug developers and researchers have discovered that delivering CNS therapeutic drugs via inhalation mitigates several of these issues. The accessibility and vascular structure of the nose make it an attractive route for delivering both small molecule drugs and biologics across the blood-brain barrier to the CNS. Pulmonary delivery to the deep lung can have favorable pharmacokinetics. And inhaled delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs. These potential advantages have spurred activity in inhaled CNS therapeutics for a range of disorders. As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient-friendly and cost-effective. Our analysis indicated that inhaled CNS administration is well positioned to take advantage of these trends and evolve into a significant factor in the future of pharmaceutical development and commercialization of CNS therapeutic drugs.

Market Data

The study presents qualitative and quantitative data and information on key market measures and benchmarks:

— CNS Disease & Disorders Sector Analysis

— Industry Structure & Competitive Landscape

— Therapeutic Product Analysis

— Company Profiles

— Inhaled Drug Technology Issues

— Alliances and Strategies

— Economic Factors

— Product Status & Prospects

— Demographic Demand Drivers

— Regulatory Factors

— Technology Risk Factors

— Forecasts & Projections to 2011

 Key Topics Covered: Executive Summary Drug Delivery Market Dynamics - The Trend toward Self-Administration - Demographic Shifts - Managed Care Initiatives - Growth in Home Healthcare - Technology Market Drivers CNS Therapeutic Sector Assessment - Alzheimer's - ADHD - Autism - Dementia - Depression - Epilepsy - Migraine - Multiple Sclerosis - Nausea - Pain Management - Parkinson's - Schizophrenia - Sleeping disorders - Stroke Inhaled Drug Development Factors - Absorption - Bioavailability - Device Design Parameters - Nasal Delivery Pharmacokinetics - Nasal Device Characteristics - Pulmonary Delivery Pharmacokinetics - Pulmonary Device Characteristics Market Factors - FDA Regulations - Clinical Trials - Rx-to-OTC Switching - Impact of Generics FDA-Approved Inhaled CNS Drug Products - Butorphanol - Imitrex - Migranal - Zomig Development-Stage Inhaled CNS Drug Products - Apomorphine - Carbetocin - Dronabinol - Dihydroergotomine - Emitasol - Fentanyl - Ketamine - Loxapine - Morphine - Prochlorperazine - Rylomine - Triazolam Sector Participant Company Profiles Table of Contents 

For more information visit http://www.researchandmarkets.com/research/370328/inhaled_cns_therap




comments powered by Disqus